Kathryn V Papp1, Dorene M Rentz2, Elizabeth C Mormino2, Aaron P Schultz2, Rebecca E Amariglio2, Yakeel Quiroz2, Keith A Johnson2, Reisa A Sperling2. 1. From the Center for Alzheimer Research and Treatment (K.V.P., D.M.R., R.E.A., K.A.J., R.A.S.), Department of Neurology, Brigham and Women's Hospital, Harvard Medical School; Department of Neurology (D.M.R., E.C.M., A.P.S., K.A.J., R.A.S.), Department of Psychiatry (Y.Q.), and Division of Nuclear Medicine and Molecular Imaging (K.A.J.), Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston; and Athinoula A. Martinos Center for Biomedical Imaging (A.P.S.), Massachusetts General Hospital, Charlestown. kpapp@partners.org. 2. From the Center for Alzheimer Research and Treatment (K.V.P., D.M.R., R.E.A., K.A.J., R.A.S.), Department of Neurology, Brigham and Women's Hospital, Harvard Medical School; Department of Neurology (D.M.R., E.C.M., A.P.S., K.A.J., R.A.S.), Department of Psychiatry (Y.Q.), and Division of Nuclear Medicine and Molecular Imaging (K.A.J.), Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston; and Athinoula A. Martinos Center for Biomedical Imaging (A.P.S.), Massachusetts General Hospital, Charlestown.
Abstract
OBJECTIVE: To determine whether a decline in cued recall is observable in the preclinical stage of Alzheimer disease (AD) in clinically normal older adults with elevated β-amyloid (Aβ) burden on PET imaging. METHODS: Clinically normal older adults underwent baseline neuroimaging (PET to assess Aβ+/- status and MRI) and annual neuropsychological testing. Cox proportional hazards models were used to assess the relative risk of cued memory decline (drop of 1, 2, 3, or 4 points on the total score of the Free and Cued Selective Reminding Test) in relation to neuroimaging measures, functional status, age, sex, and education. RESULTS: A total of 276 older adults (Clinical Dementia Rating = 0, mean Mini-Mental State Examination score = 29 ± 1.06) were followed up for a mean of 3.6 ± 1.2 years. Despite the infrequency of cued memory decline (only 19% of participants scored ≤46/48 in total recall by year 3), Aβ+ participants were 3.55 times (95% confidence interval = 1.77-7.12) more likely to exhibit decline in total recall (≤46/48) compared with their Aβ- peers. Furthermore, Aβ+ participants who scored ≤46/48 had smaller hippocampal volumes (t = 3.37, p = 0.001) and evidence of early functional decline, i.e., greater risk of progression to global Clinical Dementia Rating of 0.5 (χ2 = 14.30, p < 0.001), compared with their Aβ+ peers with intact total recall. CONCLUSIONS: Cued memory decline in healthy older adults may be particularly indicative of Aβ-related decline during the preclinical stage of AD and useful for identifying Aβ+ clinically normal individuals at greatest risk of short-term clinical progression.
OBJECTIVE: To determine whether a decline in cued recall is observable in the preclinical stage of Alzheimer disease (AD) in clinically normal older adults with elevated β-amyloid (Aβ) burden on PET imaging. METHODS: Clinically normal older adults underwent baseline neuroimaging (PET to assess Aβ+/- status and MRI) and annual neuropsychological testing. Cox proportional hazards models were used to assess the relative risk of cued memory decline (drop of 1, 2, 3, or 4 points on the total score of the Free and Cued Selective Reminding Test) in relation to neuroimaging measures, functional status, age, sex, and education. RESULTS: A total of 276 older adults (Clinical Dementia Rating = 0, mean Mini-Mental State Examination score = 29 ± 1.06) were followed up for a mean of 3.6 ± 1.2 years. Despite the infrequency of cued memory decline (only 19% of participants scored ≤46/48 in total recall by year 3), Aβ+ participants were 3.55 times (95% confidence interval = 1.77-7.12) more likely to exhibit decline in total recall (≤46/48) compared with their Aβ- peers. Furthermore, Aβ+ participants who scored ≤46/48 had smaller hippocampal volumes (t = 3.37, p = 0.001) and evidence of early functional decline, i.e., greater risk of progression to global Clinical Dementia Rating of 0.5 (χ2 = 14.30, p < 0.001), compared with their Aβ+ peers with intact total recall. CONCLUSIONS: Cued memory decline in healthy older adults may be particularly indicative of Aβ-related decline during the preclinical stage of AD and useful for identifying Aβ+ clinically normal individuals at greatest risk of short-term clinical progression.
Authors: Andrew J Aschenbrenner; David A Balota; Chi-Shing Tse; Anne M Fagan; David M Holtzman; Tammie L S Benzinger; John C Morris Journal: Neuropsychology Date: 2014-09-15 Impact factor: 3.295
Authors: Ronald C Petersen; Heather J Wiste; Stephen D Weigand; Walter A Rocca; Rosebud O Roberts; Michelle M Mielke; Val J Lowe; David S Knopman; Vernon S Pankratz; Mary M Machulda; Yonas E Geda; Clifford R Jack Journal: JAMA Neurol Date: 2016-01 Impact factor: 18.302
Authors: Murat Bilgel; Yang An; Andrew Lang; Jerry Prince; Luigi Ferrucci; Bruno Jedynak; Susan M Resnick Journal: Alzheimers Dement Date: 2014-07-14 Impact factor: 21.566
Authors: Reisa A Sperling; Peter S Laviolette; Kelly O'Keefe; Jacqueline O'Brien; Dorene M Rentz; Maija Pihlajamaki; Gad Marshall; Bradley T Hyman; Dennis J Selkoe; Trey Hedden; Randy L Buckner; J Alex Becker; Keith A Johnson Journal: Neuron Date: 2009-07-30 Impact factor: 17.173
Authors: Michael Seidenberg; Leslie Guidotti; Kristy A Nielson; John L Woodard; Sally Durgerian; Qi Zhang; Amelia Gander; Piero Antuono; Stephen M Rao Journal: J Int Neuropsychol Soc Date: 2009-01 Impact factor: 2.892
Authors: Chester A Mathis; Yanming Wang; Daniel P Holt; Guo-Feng Huang; Manik L Debnath; William E Klunk Journal: J Med Chem Date: 2003-06-19 Impact factor: 7.446
Authors: Dorene M Rentz; Mario A Parra Rodriguez; Rebecca Amariglio; Yaakov Stern; Reisa Sperling; Steven Ferris Journal: Alzheimers Res Ther Date: 2013-11-21 Impact factor: 6.982
Authors: Murat Bilgel; Yang An; Jessica Helphrey; Wendy Elkins; Gabriela Gomez; Dean F Wong; Christos Davatzikos; Luigi Ferrucci; Susan M Resnick Journal: Brain Date: 2018-08-01 Impact factor: 13.501
Authors: Edmarie Guzmán-Vélez; Jairo Martínez; Kate Papp; Ana Baena; Clara Vila-Castelar; Arabiye Artola; Aaron P Schultz; Yamile Bocanegra; Justin Sanchez; Dorene Rentz; Pierre N Tariot; Eric M Reiman; Reisa Sperling; Keith A Johnson; Francisco Lopera; Yakeel T Quiroz Journal: Neurology Date: 2020-07-01 Impact factor: 9.910
Authors: Ellen Grober; Cuiling Wang; Melissa Kitner-Triolo; Richard B Lipton; Claudia Kawas; Susan M Resnick Journal: J Int Neuropsychol Soc Date: 2021-03-22 Impact factor: 3.114
Authors: Aurélie Le Page; Hugo Garneau; Gilles Dupuis; Eric H Frost; Anis Larbi; Jacek M Witkowski; Graham Pawelec; Tamàs Fülöp Journal: Front Immunol Date: 2017-07-07 Impact factor: 7.561
Authors: Clifford R Jack; David A Bennett; Kaj Blennow; Maria C Carrillo; Billy Dunn; Samantha Budd Haeberlein; David M Holtzman; William Jagust; Frank Jessen; Jason Karlawish; Enchi Liu; Jose Luis Molinuevo; Thomas Montine; Creighton Phelps; Katherine P Rankin; Christopher C Rowe; Philip Scheltens; Eric Siemers; Heather M Snyder; Reisa Sperling Journal: Alzheimers Dement Date: 2018-04 Impact factor: 21.566
Authors: Stephane Epelbaum; Vincent Bouteloup; Jean F Mangin; Valentina La Corte; Raffaela Migliaccio; Hugo Bertin; Marie O Habert; Clara Fischer; Chabha Azouani; Ludovic Fillon; Marie Chupin; Bruno Vellas; Florence Pasquier; Jean F Dartigues; Fréderic Blanc; Audrey Gabelle; Mathieu Ceccaldi; Pierre Krolak-Salmon; Jacques Hugon; Olivier Hanon; Olivier Rouaud; Renaud David; Genevieve Chêne; Bruno Dubois; Carole Dufouil Journal: Alzheimers Dement (N Y) Date: 2018-05-22